Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose…
By N. von Beckerath, D. Taubert, G. Pogátsa-Murray, E. Schömig, A. Kastrati, A. Schömig. Circulation, 2005
661 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology
View Paper: https://www.semanticscholar.org/paper/4962816f7658865b4986c58edcc71178bbed55b3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. (2006, background): “Recent studies have shown that not only faster but greater platelet inhibition can be achieved by use of a loading dose of 600 mg of clopidogrel as compared with 300 mg.(12,26,27) This has also been associated with better protection from myocardial injury during PCI.”
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008, background): “It is started with a loading dose of at least 300 mg, but a 600 mg loading dose achieves a more rapid and stronger inhibition of platelet aggregation.(53,54) This should be followed by a daily dose of 75 mg.”